Search the Newsreel

APOLLOTYRE Outlook for the Week (August 10, 2026 – August 14, 2026)

Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 - Contact Levi & Korsinsky

A class action securities lawsuit has been filed against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made false and misleading statements regarding the efficacy of its …

PRE-MARKET INDIAN STOCKS NEWS: Earnings including Apollo Tyres, Brittania Industries, Fortis Healthcare and LIC

Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans

ATyr Pharma reported a narrower fiscal Q2 loss. The company also announced restructuring plans, with further details provided in the last three paragraphs of the article. Access to the full MT Newswires article requires a premium subscription.

FMR LLC and Abigail Johnson (ATYR) disclose 2.5% ATYR Pharma ownership

FMR LLC and Abigail P. Johnson have reported a 2.5% passive ownership stake in ATYR Pharma Inc. This disclosure, made via an amended Schedule 13G, indicates that FMR LLC beneficially owns 2,471,418 shares, with sole voting power over 2,464,141 shares and sole dispositive power …

Jefferies Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42

Jefferies has reiterated its Buy rating on TYRA BIOSCIENCES, INC. (TYRA.US) and increased its price target to $42. This indicates a positive outlook from the firm regarding the company's future performance.

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA) has received a "Moderate Buy" consensus rating from fifteen research firms, with an average 12-month price target of $46.90. Despite this optimistic outlook, the company's shares recently declined by 21% to $25.71, trading below its 50-day and 200-day moving averages. …

Tyra Biosciences (TYRA) Projected to Announce Earnings on Thursday

Tyra Biosciences (TYRA) Reports Q2 Results, Is The Pipeline Potential Already Priced In?

Tyra Biosciences (TYRA) reported Q2 2026 results, showing a wider net loss but also experiencing significant share price momentum over the past year. The article questions whether the market has already fully priced in the potential of its development pipeline, given its 1-year total …

Transcript : Styrenix Performance Materials Limited, Q1 2027 Earnings Call, Aug 05, 2026

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down Following Weak Earnings

Tyra Biosciences (NASDAQ:TYRA) shares gapped down following a disappointing earnings announcement, missing the consensus EPS estimate. Despite this, analyst sentiment remains "Moderate Buy" with an average price target of $47.00. Institutional ownership is high at 84.14%, with several major investors increasing their stakes.

TYRA Shares Drop Amid Market Volatility; Price-to-Sales Highligh

STYRENIX: Strong profit and margin growth achieved despite lower volumes and ongoing market volatility

Earnings call transcript: Styrenix Q1 2026 profits jump as volumes fall

Shareholders of aTyr Pharma, Inc. (ATYR): Protect Your Rights Before December 8, 2025 - Contact Levi & Korsinsky

Levi & Korsinsky LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements regarding the …

Tyra Biosciences posts Q2 2026 net loss $45.6M; cash $353.9M, runway into 2H 2028

Tyra Biosciences reported a Q2 2026 net loss of $45.6 million, ending the quarter with $353.9 million in cash, cash equivalents, and marketable securities, providing a runway into the second half of 2028. The company is advancing its dabogratinib programs, with key clinical readouts …

BlackRock, Inc. Expands Tyra Biosciences (TYRA) Stake with Strat

Tyra Biosciences (NASDAQ:TYRA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Tyra Biosciences 2Q 2026: Net loss $45.6M, EPS $(0.69) — 10-Q Summary

Tyra Biosciences reported a net loss of $45.6 million, or $(0.69) per diluted share, for the second quarter of 2026, which is an increase from the $28.1 million net loss in the prior year. The company maintains a strong liquidity position with $353.9 million …

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences announced its second-quarter 2026 financial results, highlighted by initial Phase 2 data from SURF302 for bladder cancer expected in September 2026 and an expanded fifth dose level for the BEACH301 study in achondroplasia. The company reported $353.9 million in cash, cash equivalents, …

LIFE|aTyr Pharma Ord Shs|Price:22.810|Chg%:+2.390

Small-cap chemicals firm Styrenix declares ₹23/share interim dividend for shareholders; check record date

Styrenix Performance Materials consolidated net profit rises 166.37% in the June 2026 quarter

Class Action Filed Against aTyr Pharma, Inc. (ATYR) Over Securities Violations – Contact Levi & Korsinsky Today

A class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) alleging securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims the company made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to reduce steroid …

Apollo Tyres Shares Rise 2.13% to Rs 437.25

Arkadios Wealth Advisors Makes New $1.82 Million Investment in Tyra Biosciences, Inc. $TYRA

Arkadios Wealth Advisors has made a new investment of $1.82 million in Tyra Biosciences, Inc., acquiring 47,567 shares. This comes as institutional investors and hedge funds collectively own a significant 84.14% of the company. Despite Tyra Biosciences missing its Q1 earnings estimates, analysts maintain …

Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn

MarketScreener has withdrawn alerts regarding Ethos Technologies' Q2 results that were erroneously attributed to aTyr Pharma, Inc. The original publication was made on August 3, 2026, at 04:48 pm EDT by Reuters. This correction highlights a data misattribution concerning financial reporting.

aTyr Pharma Inc expected to post a loss of 12 cents a share - Earnings Preview

aTyr Pharma Inc is projected to report a loss of 12 cents per share, according to an earnings preview. This information is sourced from Refinitiv and was published by Reuters. The full article is available on TradingView, which aggregates news from various sources.

Tyra Biosciences, Inc. $TYRA Stock Position Boosted by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP significantly increased its stake in Tyra Biosciences (TYRA) by 149.6% in Q1 2026, holding 198,585 shares worth $7.6 million. This move is part of a broader trend of institutional investment, with several other firms also boosting their positions. Analysts …

Discipline and Rules-Based Execution in TYRA Response

This article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA) using AI models to provide trading strategies. It highlights positive near-term sentiment within a long-term strength context, noting that support is being tested. The analysis identifies an exceptional risk-reward setup and offers distinct position, momentum breakout, …

LIFE|aTyr Pharma Ord Shs|Price:20.500|Chg%:+0.080

BlackRock (TYRA holder) reports 2.98M TYRA Biosciences shares, a 5% passive stake

BlackRock, Inc. has reported a 5% passive ownership stake in TYRA Biosciences, Inc., beneficially owning 2,976,228 shares of common stock. BlackRock holds sole voting power over 2,924,904 shares and sole dispositive power over all its beneficially owned shares. The filing indicates that no single …

aTyr Pharma Inc (ATYR) Financial Health: Profitability & Balance Sheet Analysis

aTyr Pharma Inc (ATYR) currently holds a financial score of 6.87, ranking 190 out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status and low operating efficiency. The report highlights that relevant financial data for Quality of Earnings, Operational …

Tyra Biosciences, Inc. $TYRA Shares Sold by Eversept Partners LP

Eversept Partners LP drastically reduced its stake in Tyra Biosciences (NASDAQ:TYRA) by 90.3% in the first quarter, selling over 251,000 shares. Despite this, institutional investors still collectively own a significant 84.14% of the company's stock, and Wall Street analysts maintain a "Moderate Buy" consensus …

ATYR|aTyr Pharma Inc|Price:0.499|Chg%:+0.010

This article presents a comprehensive stock analysis of aTyr Pharma Inc (ATYR) by TradingKey, highlighting its fundamental stability, high growth potential, and a fairly valued assessment within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company shows strong fundamentals …

aTyr Pharma Inc (ATYR) Institutional Confidence

The article details the institutional confidence score for aTyr Pharma Inc (ATYR), which is 5.00, placing it 132nd in the Biotechnology & Medical Research industry. It highlights a 24.02% quarter-over-quarter decrease in institutional shareholding proportion to 56.72%. The largest institutional shareholder is James Simons, …